Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BYMASTER FP' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 77 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Skolnick, P; Legutko, B; Li, X; Bymaster, FP
      Current perspectives on the development of non-biogenic amine-based antidepressants

      PHARMACOLOGICAL RESEARCH
    2. Rasmussen, T; Fink-Jensen, A; Sauerberg, P; Swedberg, MDB; Thomsen, C; Sheardown, MJ; Jeppesen, L; Calligaro, DO; DeLapp, NW; Whitesitt, C; Ward, JS; Shannon, HE; Bymaster, FP
      The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance

      SCHIZOPHRENIA RESEARCH
    3. Du, YS; Ma, ZZ; Lin, SZ; Dodel, RC; Gao, F; Bales, KR; Triarhou, LC; Chernet, E; Perry, KW; Nelson, DLG; Luecke, S; Phebus, LA; Bymaster, FP; Paul, SM
      Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    4. Yamada, M; Lamping, KG; Duttaroy, A; Zhang, WL; Cui, YH; Bymaster, FP; McKinzie, DL; Felder, CC; Deng, CX; Faraci, FM; Wess, J
      Cholinergic dilation of cerebral blood vessels is abolished in M-5 muscarinic acetylcholine receptor knockout mice

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    5. Gomeza, J; Zhang, L; Kostenis, E; Felder, CC; Bymaster, FP; Brodkin, J; Shannon, H; Xia, B; Duttaroy, A; Deng, CX; Wess, J
      Generation and pharmacological analysis of M-2 and M-4 muscarinic receptorknockout mice

      LIFE SCIENCES
    6. Bymaster, FP; Carter, PA; Zhang, L; Falcone, JF; Stengel, PW; Cohen, ML; Shannon, HE; Gomeza, J; Wess, J; Felder, CC
      Investigations into the physiological role of muscarinic M-2 and M-4 muscarinic and M-4 receptor subtypes using receptor knockout mice

      LIFE SCIENCES
    7. Felder, CC; Porter, AC; Skillman, TL; Zhang, L; Bymaster, FP; Nathanson, NM; Hamilton, SE; Gomeza, J; Wess, J
      Elucidating the role of muscarinic receptors in psychosis

      LIFE SCIENCES
    8. Bymaster, FP; Falcone, JF; Bauzon, D; Kennedy, JS; Schenck, K; DeLapp, NW; Cohen, ML
      Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    9. Tzavara, ET; Perry, KW; Rodriguez, DE; Bymaster, FP; Nomikos, GG
      The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrineoutflow in the rat anterior hypothalamus

      EUROPEAN JOURNAL OF PHARMACOLOGY
    10. Bymaster, FP; Carter, PA; DeLapp, NW; Calligaro, DO; Felder, CC
      Receptor reserve of phosphoinositide-coupled muscarinic receptors in mousehippocampus in vivo

      BRAIN RESEARCH
    11. Perry, KW; Nisenbaum, LK; George, CA; Shannon, HE; Felder, CC; Bymaster, FP
      The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

      BIOLOGICAL PSYCHIATRY
    12. Shelton, RC; Tollefson, GD; Tohen, M; Stahl, S; Gannon, KS; Jacobs, TG; Buras, WR; Bymaster, FP; Zhang, W; Spencer, KA; Feldman, PD; Meltzer, HY
      A novel augmentation strategy for treating resistant major depression

      AMERICAN JOURNAL OF PSYCHIATRY
    13. Shannon, HE; Rasmussen, K; Bymaster, FP; Hart, JC; Peters, SC; Swedberg, MDB; Jeppesen, L; Sheardown, MJ; Sauerberg, P; Fink-Jensen, A
      Xanomeline, an M-1/M-4 preferring muscarinic cholinergic receptor agonist,produces antipsychotic-like activity in rats and mice

      SCHIZOPHRENIA RESEARCH
    14. Zhang, W; Perry, KW; Wong, DT; Potts, BD; Bao, JQ; Tollefson, GD; Bymaster, FP
      Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex

      NEUROPSYCHOPHARMACOLOGY
    15. Felder, CC; Bymaster, FP; Ward, J; DeLapp, N
      Therapeutic opportunities for muscarinic receptors in the central nervous system

      JOURNAL OF MEDICINAL CHEMISTRY
    16. Rasmussen, T; Sauerberg, P; Nielsen, EB; Swedberg, MDB; Thomsen, C; Sheardown, MJ; Jeppesen, L; Calligaro, DO; DeLapp, NW; Whitesitt, C; Ward, JS; Shannon, HE; Bymaster, FP; Fink-Jensen, A
      Muscarinic receptor agonists decrease cocaine self-administration rates indrug-naive mice

      EUROPEAN JOURNAL OF PHARMACOLOGY
    17. Bymaster, FP; Falcone, JF
      Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

      EUROPEAN JOURNAL OF PHARMACOLOGY
    18. Street, JS; Clark, WS; Gannon, KS; Cummings, JL; Bymaster, FP; Tamura, RN; Mitan, SJ; Kadam, DL; Sanger, TM; Feldman, PD; Tollefson, GD; Breier, A
      Olanzapine treatment of psychotic and behavioral symptoms in patients withAlzheimer disease in nursing care facilities - A double-blind, randomized,placebo-controlled trial

      ARCHIVES OF GENERAL PSYCHIATRY
    19. Bymaster, FP; Nelson, DL; DeLapp, NW; Falcone, JF; Eckols, K; Truex, LL; Foreman, MM; Lucaites, VL; Calligaro, DO
      Antagonism by olanzapine of dopamine D1, serotonin(2), muscarinic, histamine H-1 and alpha(1),-adrenergic receptors in vitro

      SCHIZOPHRENIA RESEARCH
    20. Bymaster, FP; Calligaro, DO; Falcone, JF
      Arachidonic acid release in cell tines transfected with muscarinic receptors: A simple functional assay to determine response of agonists

      CELLULAR SIGNALLING
    21. Sawyer, BD; Bymaster, FP; Calligaro, DO; Falcone, J; Mitch, CH; Ward, JS; Whitesitt, C; Shannon, HE
      Direct pharmacological comparison of the muscarinic receptors mediating relaxation and contraction in the rabbit thoracic aorta

      GENERAL PHARMACOLOGY
    22. Bymaster, FP; Shannon, HE; Rasmussen, K; DeLapp, NW; Ward, JS; Calligaro, DO; Mitch, CH; Whitesitt, C; Ludvigsen, TS; Sheardown, M; Swedberg, M; Rasmussen, T; Olesen, PH; Jeppesen, L; Sauerberg, P; Fink-Jensen, A
      Potential role of muscarinic receptors in schizophrenia

      LIFE SCIENCES
    23. Shannon, HE; Hart, JC; Bymaster, FP; Calligaro, DO; Delapp, NW; Mitch, CH; Ward, JS; Fink-Jensen, A; Sauerberg, P; Jeppesen, L; Sheardown, MJ; Swedberg, MDB
      Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    24. Jeppesen, L; Olesen, PH; Hansen, L; Sheardown, MJ; Thomsen, C; Rasmussen, T; Jensen, AF; Christensen, MS; Rimvall, K; Ward, JS; Whitesitt, C; Calligaro, DO; Bymaster, FP; Delapp, NW; Felder, CC; Shannon, HE; Sauerberg, P
      1-(1,2,5-thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M-1 agonists: Structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives

      JOURNAL OF MEDICINAL CHEMISTRY
    25. Zhang, W; Bymaster, FP
      The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscarinic receptors

      PSYCHOPHARMACOLOGY
    26. SAUERBERG P; JEPPESEN L; OLESEN PH; SHEARDOWN MJ; FINKJENSEN A; RASMUSSEN T; RIMVALL K; SHANNON HE; BYMASTER FP; DELAPP NW; CALLIGARO DO; WARD JS; WHITESITT CA; THOMSEN C
      IDENTIFICATION OF SIDE-CHAINS ON 1,2,5-THIADIAZOLE-AZACYCLES OPTIMAL FOR MUSCARINIC M1 RECEPTOR ACTIVATION

      Bioorganic & medicinal chemistry letters
    27. Fink-Jensen, A; Kristensen, P; Shannon, HE; Calligaro, DO; Delapp, NW; Whitesitt, C; Ward, JS; Thomsen, C; Rasmusseen, T; Sheardown, MJ; Jeppesen, L; Sauerberg, P; Bymaster, FP
      Muscarinic agonists exhibit functional dopamine antagonism in unilaterally6-OHDA lesioned rats

      NEUROREPORT
    28. SHANNON HE; BYMASTER FP; BODICK NW; OFFEN WW; DELAPP NC; PERRY KW; RASMUSSEN K; WARD JS; WHITESITT CA; FINKJENSEN A; OLESEN P; RASMUSSEN T; SHEARDOWN M; SWEDBERG M; SAUERBERG P
      MUSCARINIC AGENTS - A NEW APPROACH TO THE TREATMENT OF PSYCHOSIS

      Schizophrenia research
    29. ZHANG W; PERRY KW; BYMASTER FP
      IN-VIVO EFFECTS OF OLANZAPINE ON RADIOLIGAND BINDING, DOPAMINE D2 AUTORECEPTOR BLOCKADE, AGONIST-INDUCED IN-VIVO PHOSPHOINOSITIDE HYDROLYSIS AND NEUROTRANSMITTER RELEASE

      Schizophrenia research
    30. RASMUSSEN TR; SWEDBERG MDB; BYMASTER FP
      OLANZAPINE - ANTIDOPAMINERGIC AND MEMORY EFFECTS IN MICE

      Schizophrenia research
    31. WARD JS; MERRITT L; CALLIGARO DO; BYMASTER FP; SHANNON HE; MITCH CH; WHITESITT C; BRUNSTING D; SHEARDOWN MJ; OLESEN PH; SWEDBERG MDB; JEPPESEN L; SAUERBERG P
      1,2,5-THIADIAZOLE ANALOGS OF ACECLIDINE AS POTENT M(1) MUSCARINIC AGONISTS

      Journal of medicinal chemistry
    32. SAUERBERG P; JEPPESEN L; OLESEN PH; RASMUSSEN T; SWEDBERG MDB; SHEARDOWN MJ; FINKJENSEN A; THOMSEN C; THOGERSEN H; RIMVALL K; WARD JS; CALLIGARO DO; DELAPP NW; BYMASTER FP; SHANNON HE
      MUSCARINIC AGONISTS WITH ANTIPSYCHOTIC-LIKE ACTIVITY - STRUCTURE-ACTIVITY-RELATIONSHIPS OF 1,2,5-THIADIAZOLE ANALOGS WITH FUNCTIONAL DOPAMINE ANTAGONIST ACTIVITY

      Journal of medicinal chemistry
    33. SAUERBERG P; OLESEN PH; SHEARDOWN MJ; RIMVALL K; THOGERSEN H; SHANNON HE; SAWYER BD; WARD JS; BYMASTER FP; DELAPP NW; CALLIGARO DO; SWEDBERG MDB
      CONFORMATIONALLY CONSTRAINED ANALOGS OF THE MUSCARINIC AGONIST IADIAZOL-3-YL)-1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE - SYNTHESIS, RECEPTOR AFFINITY, AND ANTINOCICEPTIVE ACTIVITY

      Journal of medicinal chemistry
    34. BYMASTER FP; SHANNON HE; RASMUSSEN K; DELAPP NW; MITCH CH; WARD JS; CALLIGARO DO; LUDVIGSEN TS; SHEARDOWN MJ; OLESEN PH; SWEDBERG MDB; SAUERBERG P; FINKJENSEN A
      UNEXPECTED ANTIPSYCHOTIC-LIKE ACTIVITY WITH THE MUSCARINIC RECEPTOR-LIGAND O-1,2,5-THIADIAZOL-4-YL)-1-AZABICYCLO[3.2.1]OCTANE

      European journal of pharmacology
    35. BYMASTER FP; CARTER PA; PETERS SC; ZHANG W; WARD JS; MITCH CH; CALLIGARO DO; WHITESITT CA; DELAPP N; SHANNON HE; RIMVALL K; JEPPESEN L; SHEARDOWN MJ; FINKJENSEN A; SAUERBERG P
      XANOMELINE COMPARED TO OTHER MUSCARINIC AGENTS ON STIMULATION OF PHOSPHOINOSITIDE HYDROLYSIS IN-VIVO AND OTHER CHOLINOMIMETIC EFFECTS

      Brain research
    36. LI XM; PERRY KW; WONG DT; BYMASTER FP
      OLANZAPINE INCREASES IN-VIVO DOPAMINE AND NOREPINEPHRINE RELEASE IN RAT PREFRONTAL CORTEX, NUCLEUS-ACCUMBENS AND STRIATUM

      Psychopharmacology
    37. BRIGHT SW; HIGGINBOTHAM JD; COFIELD DJ; FALCONE JF; BYMASTER FP
      DEVELOPMENT OF A WHOLE-CELL HIGH-THROUGHPUT SCREEN FOR MUSCARINIC RECEPTOR AGONISTS

      Journal of biomolecular screening
    38. BYMASTER FP; LI XM; CARTER PA; WONG DT; PERRY KW
      OLANZAPINE INCREASES EXTRACELLULAR DOPAMINE RELEASE AND BLOCKS DOPAMINE, SEROTONIN AND MUSCARINIC RECEPTORS IN-VIVO

      Schizophrenia research
    39. BYMASTER FP; WHITESITT CA; SHANNON HE; DELAPP N; WARD JS; CALLIGARO DO; SHIPLEY LA; BUELKESAM JL; BODICK NC; FARDE L; SHEARDOWN MJ; OLESEN PH; HANSEN KT; SUZDAK PD; SWEDBERG MDB; SAUERBERG P; MITCH CH
      XANOMELINE - A SELECTIVE MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE

      Drug development research
    40. BYMASTER FP; RASMUSSEN K; CALLIGARO DO; NELSON DL; DELAPP NW; WONG DT; MOORE NA
      IN-VITRO AND IN-VIVO BIOCHEMISTRY OF OLANZAPINE - A NOVEL, ATYPICAL ANTIPSYCHOTIC DRUG

      The Journal of clinical psychiatry
    41. SAUERBERG P; OLESEN PH; THOGERSEN H; NIELSEN S; SHEARDOWN MJ; RIMVALL K; SHANNON HE; WARD JS; MITCH CH; BYMASTER FP; SWEDBERG MDB
      CONFORMATIONALLY CONSTRAINED ANALOGS OF THE MUSCARINIC AGONIST METHYLTHIO-TZTP - SYNTHESIS, RECEPTOR AFFINITY AND ANALGESIC ACTIVITY

      Life sciences
    42. WARD JS; MERRITT L; STRATFORD R; BROWN TJ; WIJAYARATNE R; SZEWCZYK SP; CALLIGARO DO; BYMASTER FP; SHANNON HE; MITCH CH; JOHNSON DW; WIKEL JH; OLESEN MJ; SHEARDOWN MJ; SWEDBERG MDB; SAUERBERG P
      THE TETRAHYDROPYRIDINE RING CONFERS OPTIMAL M(1) SELECTIVITY AND BLOOD-BRAIN-BARRIER PENETRATION AMONG HEXYLOXY-1,2,5-THIADIAZOLE AZACYCLES

      Life sciences
    43. SHANNON HE; WOMER DE; DELAPP NW; BYMASTER FP; MITCH CH; WARD JS; WHITESITT C; CALLIGARO D; SWEDBERG MDB; SHEARDOWN MJ; SAUERBERG P; RIMVALL K; FINKJENSEN A; JEPPESEN L
      MUSCARINIC AGONISTS PRODUCE ANALGESIA THROUGH PERTUSSIS-TOXIN-SENSITIVE MUSCARINIC RECEPTORS IN THE SPINAL-CORD

      Life sciences
    44. SWEDBERG MDB; SHANNON HE; SHEARDOWN MJ; KLITGAARD H; BYMASTER FP; WARD JS; MITCH CH; OLESEN PH; ESKESEN K; SUZDAK PD; CALLIGARO DO; SAUERBERG P
      ANTICONVULSANT EFFECTS OF MUSCARINICS

      Life sciences
    45. SHANNON HE; WOMER DE; BYMASTER FP; CALLIGARO DO; DELAPP NC; MITCH CH; WARD JS; WHITESITT CA; SWEDBERG MDB; SHEARDOWN MJ; FINKJENSEN A; OLESEN PH; RIMVALL K; SAUERBERG P
      IN-VIVO PHARMACOLOGY OF BUTYLTHIO[2.2.2] (LY297802 NNC11-1053), AN ORALLY ACTING ANTINOCICEPTIVE MUSCARINIC AGONIST/

      Life sciences
    46. SHEARDOWN MJ; SHANNON HE; SWEDBERG MDB; SUZDAK PD; BYMASTER FP; OLESEN PH; MITCH CH; WARD JS; SAUERBERG P
      M-1 RECEPTOR AGONIST ACTIVITY IS NOT A REQUIREMENT FOR MUSCARINIC ANTINOCICEPTION

      The Journal of pharmacology and experimental therapeutics
    47. SWEDBERG MDB; SHEARDOWN MJ; SAUERBERG P; OLESEN PH; SUZDAK PD; HANSEN KT; BYMASTER FP; WARD JS; MITCH CH; CALLIGARO DO; DELAPP NW; SHANNON HE
      BUTYLTHIO[2.2.2] (NNC 11-1053 LY297802) - AN ORALLY-ACTIVE MUSCARINICAGONIST ANALGESIC/

      The Journal of pharmacology and experimental therapeutics
    48. SHANNON HE; SHEARDOWN MJ; BYMASTER FP; CALLIGARO DO; DELAPP NW; GIDDA J; MITCH CH; SAWYER BD; STENGEL PW; WARD JS; WONG DT; OLESEN PH; SUZDAK PD; SAUERBERG P; SWEDBERG MDB
      PHARMACOLOGY OF BUTYLTHIO[2.2.2] (LY297802 NNC11-1053) - A NOVEL ANALGESIC WITH MIXED MUSCARINIC RECEPTOR AGONIST AND ANTAGONIST ACTIVITY/

      The Journal of pharmacology and experimental therapeutics
    49. MITCH CH; BROWN TJ; BYMASTER FP; CALLIGARO DO; DIECKMAN D; MERRIT L; PETERS SC; QUIMBY SJ; SHANNON HE; SHIPLEY LA; WARD JS; HANSEN K; OLESEN PH; SAUERBERG P; SHEARDOWN MJ; SWEDBERG MDB; SUZDAK P; GREENWOOD B
      MUSCARINIC ANALGESICS WITH POTENT AND SELECTIVE EFFECTS ON THE GASTROINTESTINAL-TRACT - POTENTIAL APPLICATION FOR THE TREATMENT OF IRRITABLE-BOWEL-SYNDROME

      Journal of medicinal chemistry
    50. BODICK NC; OFFEN WW; LEVEY AI; CUTLER NR; GAUTHIER SG; SATLIN A; SHANNON HE; TOLLEFSON GD; RASMUSSEN K; BYMASTER FP; HURLEY DJ; POTTER WZ; PAUL SM
      EFFECTS OF XANOMELINE, A SELECTIVE MUSCARINIC RECEPTOR AGONIST, ON COGNITIVE FUNCTION AND BEHAVIORAL SYMPTOMS IN ALZHEIMER-DISEASE

      Archives of neurology
    51. FARDE L; SUHARA T; HALLDIN C; NYBACK H; NAKASHIMA Y; SWAHN CG; KARLSSON P; GINOVART N; BYMASTER FP; SHANNON HE; FOGED C; SUZDAK PD; SAUERBERG P
      PET STUDY OF THE M(1)-AGONISTS [C-11] XANOMELINE AND [C-11] BUTYLTHIO-TZTP IN MONKEY AND MAN

      Dementia
    52. BYMASTER FP; NELSON DL; DELAPP NW; LUCAITES VL; WAINSCOTT DB; FALCONE JF; ECKOLS K; FOREMAN MM; CALLIGARO DO
      THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE IS AN ANTAGONIST AT DOPAMINE, SEROTONIN AND MUSCARINIC RECEPTOR SUBTYPES

      Schizophrenia research
    53. BYMASTER FP; CALLIGARO DO; FALCONE JF; MARSH RD; MOORE NA; TYE NC; SEEMAN P; WONG DT
      RADIORECEPTOR BINDING PROFILE OF THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE

      Neuropsychopharmacology
    54. OLESEN PH; SAUERBERG P; TREPPENDAHL S; LARSSON O; SHEARDOWN MJ; SUZDAK PD; MITCH CH; WARD JS; BYMASTER FP; SHANNON HE; SWEDBERG MDB
      3-(3-ALKYLTHIO-1,2,5-THIADIAZOL-4-YL)1-AZABICYCLE - STRUCTURE-ACTIVITY-RELATIONSHIPS FOR ANTINOCICEPTION MEDIATED BY CENTRAL MUSCARINIC RECEPTORS

      European journal of medicinal chemistry
    55. BYMASTER FP; HEMRICKLUECKE SK; PERRY KW; FULLER RW
      NEUROCHEMICAL EVIDENCE FOR ANTAGONISM BY OLANZAPINE OF DOPAMINE, SEROTONIN, ALPHA(1)-ADRENERGIC AND MUSCARINIC RECEPTORS IN-VIVO IN RATS

      Psychopharmacology
    56. BYMASTER FP; FALCONE JF; HEMRICKLUECKE SK; PERRY KW; FULLER RW
      THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE BLOCKS MUSCARINIC, SEROTONERGICAND DOPAMINE-RECEPTORS

      Schizophrenia research
    57. BAUMGOLD J; DYER K; FALCONE JF; BYMASTER FP
      COMPARISON OF 2ND-MESSENGER RESPONSES TO MUSCARINIC RECEPTOR STIMULATION IN M1-TRANSFECTED A9-L-CELLS

      Cellular signalling
    58. WONG DT; BYMASTER FP; ENGLEMAN EA
      PROZAC (FLUOXETINE, LILLY-110140), THE FIRST SELECTIVE SEROTONIN UPTAKE INHIBITOR AND AN ANTIDEPRESSANT DRUG - 20 YEARS SINCE ITS FIRST PUBLICATION

      Life sciences
    59. ECKOLS K; BYMASTER FP; MITCH CH; SHANNON HE; WARD JS; DELAPP NW
      THE MUSCARINIC M1 AGONIST XANOMELINE INCREASES SOLUBLE AMYLOID PRECURSOR PROTEIN RELEASE FROM CHINESE-HAMSTER OVARY-M1 CELLS

      Life sciences
    60. SAUERBERG P; OLESEN PH; SHEARDOWN MJ; SUZDAK PD; SHANNON HE; BYMASTER FP; CALLIGARO DO; MITCH CH; WARD JS; SWEDBERG MDB
      MUSCARINIC AGONISTS AS ANALGESICS - ANTINOCICEPTIVE ACTIVITY VERSUS M(1) ACTIVITY - SAR OF ALKYLTHIO-TZTPS AND RELATED 1,2,5-THIADIAZOLE ANALOGS

      Life sciences
    61. WARD JS; MERRITT L; CALLIGARO DO; BYMASTER FP; SHANNON HE; SAWYER BD; MITCH CH; SHEARDOWN MJ; OLESEN PH; SUZDAK PD; SWEDBERG MDB
      3-(3-HEXYLOXYPYRAZINYL) QUINUCLIDINE AS A FUNCTIONALLY SELECTIVE M(1)AGONIST

      Life sciences
    62. MITCH CH; BYMASTER FP; CALLIGARO DO; QUIMBY SJ; SAWYER BD; WARD JS; OLESEN PH; SAUERBERG P; SHEARDOWN MJ; SUZDAK PD; SWEDBERG M; SHANNON HE
      SIDE-CHAIN STERIC BULK AND MUSCARINIC AGONIST SAR IN ALKOXY-TZTPS

      Life sciences
    63. BYMASTER FP; FALCONE JF; SHANNON HE; CALLIGARO DO
      ARACHIDONIC-ACID RELEASE BY MUSCARINIC AGENTS IN CELL-LINES TRANSFECTED WITH MUSCARINIC RECEPTORS

      Life sciences
    64. DELAPP NW; ECKOLS K; BYMASTER FP; MITCH CH; SHANNON HE; WARD JS
      THE M1 AGONIST XANOMELINE POTENTLY STIMULATES APPS RELEASE FROM CHO-M1 CELLS

      Life sciences
    65. SHANNON HE; BYMASTER FP; CALLIGARO DO; MITCH CH; SAWYER BD; WARD JS; SHEARDOWN MJ; OLESEN PH; SAUERBERG P; SUZDAK PD; SWEDBERG MDB
      IN-VITRO PHARMACOLOGY OF THE MUSCARINIC ANALGESIC LY297802 NNC111053/

      Life sciences
    66. SWEDBERG MDB; SHEARDOWN MJ; SAUERBERG P; OLESEN P; SUZDAK PD; BYMASTER FP; WARD JS; MITCH CH; CALLIGARO DO; SHANNON HE
      NNC-11-1053 LY-297802 - AN ANTINOCICEPTIVE ORALLY ACTING MUSCARINIC AGONIST IN MOUSE AND RAT

      Life sciences
    67. WARD JS; MERRITT L; CALLIGARO DO; BYMASTER FP; SHANNON HE; SAWYER BD; MITCH CH; DEETER JB; PETERS SC; SHEARDOWN MJ; OLESEN PH; SWEDBERG MDB; SAUERBERG P
      FUNCTIONALLY SELECTIVE M(1) MUSCARINIC AGONISTS .3. SIDE-CHAINS AND AZACYCLES CONTRIBUTING TO FUNCTIONAL MUSCARINIC SELECTIVITY AMONG PYRAZINYLAZACYCLES

      Journal of medicinal chemistry
    68. SHANNON HE; BYMASTER FP; HENDRIX JC; QUIMBY SJ; MITCH CH
      NOVEL ALKOXY-OXAZOLYL-TETRAHYDROPYRIDINE MUSCARINIC CHOLINERGIC RECEPTOR ANTAGONISTS

      Psychopharmacology
    69. WARD JS; MERRITT L; BYMASTER FP; CALLIGARO DO
      ISOARECOLONES AND ARECOLONES - SELECTIVE CENTRAL NICOTINIC AGONISTS THAT CROSS THE BLOOD-BRAIN-BARRIER

      Bioorganic & medicinal chemistry letters
    70. QUIMBY SJ; SHANNON HE; BYMASTER FP; SAUERBERG P; OLESEN PH; SHEARDOWN MJ; SUZDAK PD; MITCH CH
      SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF ALKYL SUBSTITUTED ANALOGS OF THE FUNCTIONAL M(1) SELECTIVE MUSCARINIC RECEPTOR AGONIST XANOMELINE

      Bioorganic & medicinal chemistry letters
    71. MITCH CH; BYMASTER FP; CALLIGARO DO; QUIMBY SJ; SCHOEPP DD; WONG DT; SHANNON HE
      MUSCARINIC ANTAGONIST ACTIVITY OF (5-ALKOXY-OXAZOL-2-YL)-1,2,5,6-TETRAHYDROPYRIDINES

      Bioorganic & medicinal chemistry letters
    72. MITCH CH; BYMASTER FP; CALLIGARO DO; QUIMBY SJ; SAWYER BD; SHANNON HE; WARD JS; OLESEN PH; SAUERBERG P; SHEARDOWN MJ; SUZDAK PD
      XANOMELINE - A POTENT AND SELECTIVE M1 MUSCARINIC AGONIST IN-VITRO

      Neurobiology of aging
    73. SHANNON HE; BYMASTER FP; CALLIGARO DO; GREENWOOD B; MITCH CH; SAWYER BD; WARD JS; WONG DT; OLESEN PH; SHEARDOWN MJ; SWEDBERG MDB; SUZDAK PD; SAUERBERG P
      XANOMELINE - A NOVEL MUSCARINIC RECEPTOR AGONIST WITH FUNCTIONAL SELECTIVITY FOR M(1) RECEPTORS

      The Journal of pharmacology and experimental therapeutics
    74. BYMASTER FP; WONG DT; MITCH CH; WARD JS; CALLIGARO DO; SCHOEPP DD; SHANNON HE; SHEARDOWN MJ; OLESEN PH; SUZDAK PD; SWEDBERG MDB; SAUERBERG P
      NEUROCHEMICAL EFFECTS OF THE M(1) MUSCARINIC AGONIST XANOMELINE (LY246708 NNC11-0232)/

      The Journal of pharmacology and experimental therapeutics
    75. WONG DT; BYMASTER FP; REID LR; MAYLE DA; KRUSHINSKI JH; ROBERTSON DW
      NORFLUOXETINE ENANTIOMERS AS INHIBITORS OF SEROTONIN UPTAKE IN RAT-BRAIN

      Neuropsychopharmacology
    76. BYMASTER FP; HEATH I; HENDRIX JC; SHANNON HE
      COMPARATIVE BEHAVIORAL AND NEUROCHEMICAL ACTIVITIES OF CHOLINERGIC ANTAGONISTS IN RATS

      The Journal of pharmacology and experimental therapeutics
    77. WONG DT; THRELKELD PG; BYMASTER FP
      DOPAMINE RECEPTOR AFFINITIES INVITRO AND NEUROCHEMICAL EFFECTS INVIVOOF PERGOLIDE AND ITS METABOLITES

      Arzneimittel-Forschung


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 08:12:14